Studies recruiting patients with Membranoproliferative Glomerulonephritis
Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
Monoclonal gammopathy is a common disorder but only a small fraction of patients with monoclonal gammopathy of undetermined significance (MGUS) develop renal disease and the reason for abnormal deposition of immunoglobulin in renal parenchyma remains unclear in these disorders. The proposed research will be conducted as a part of clinical trial which intends to prospectively evaluate the effect of anti-plasma cell therapy on renal outcomes in patients with monoclonal gammopathy of renal significance (MGRS). The study specifically intends to sequence the immunoglobulin heavy and light chain genes to determine any abnormalities that could lead to production of a misfolded immunoglobulin thus leading to deposition in renal parenchyma.
Site PI: Dr. Meghan Sise
Contact: msise@mgb.org
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT)
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.
Site PI: Dr. Meghan Sise
Contact: msise@mgb.org